UNSPSC 51182041: Oxandrolone

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C19H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H6TM3CT4L, chemically known as 2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)- (9ci) but generally known as oxandrolone, which bears US NIH Compound Identifier 5878. European Medicines Agency schedules Oxandrolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09496MIG.

UNSPSC 51182041 Oxandrolone is a Commodity code for a controlled anabolic steroid pharmaceutical product used in medical settings for specific therapeutic indications such as treatment of muscle-wasting conditions, severe burns, and delayed wound healing. State and local governments procure oxandrolone primarily through public health departments, correctional healthcare systems, and hospital networks operated by county and municipal authorities to supply inpatient and outpatient clinical programs. The product is available in standardized pharmaceutical formulations (typically tablet form) and is subject to DEA scheduling, state pharmacy board licensing requirements, and federal supply-chain controls that shape procurement workflows and vendor qualifications.

The source provides no recent state and local contract opportunities tagged to UNSPSC 51182041. Activity under this Commodity code remains sparse in publicly posted state and local procurement channels, reflecting both the specialized clinical use case and the regulated pharmaceutical supply-chain environment in which oxandrolone operates. Buying agencies typically source this product through established group purchasing organizations, state pharmaceutical contracts, or standing agreements with licensed wholesale distributors rather than through competitive open solicitations, which limits visibility in posted RFP, RFQ, and IFB notice streams.